Cytokinetics
(NASDAQ) CYTK
Cytokinetics Financials at a Glance
Market Cap
$10.61B
Revenue (TTM)
$105.82M
Net Income (TTM)
-$829.61M
EPS (TTM)
-$6.84
P/E Ratio
-12.46
Dividend
$0.00
Beta (Volatility)
0.96 (Low)
Dividend
$0.00
Beta (Volatility)
0.96 (Low)
Price
$85.22
Volume
768
Open
$86.56
Price
$85.22
Volume
768
Open
$86.56
Previous Close
$85.26
Daily Range
$84.99 - $86.56
52-Week Range
$32.89 - $88.31
Estimated Earnings Date
Aug 6, 2026
Dividend
$0.00
Beta (Volatility)
0.96 (Low)
Price
$85.22
Volume
768
Open
$86.56
Previous Close
$85.26
Daily Range
$84.99 - $86.56
52-Week Range
$32.89 - $88.31
Estimated Earnings Date
Aug 6, 2026
CYTK News
CYTK: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Cytokinetics
Industry
Biotechnology
Sector
Health CareEmployees
673
CEO
Robert I. Blum, MBA
Website
www.cytokinetics.comHeadquarters
South San Francisco, CA 94080, US
CYTK Financials
Key Financial Metrics (TTM)
Gross Margin
90.34%
Operating Margin
-605.06%
Net Income Margin
-784.02%
Return on Equity
139.66%
Return on Capital
-98.02%
Return on Assets
-65.15%
Earnings Yield
-8.03%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$10.61B
Shares Outstanding
124.43M
Volume
768
Avg. Volume
2.56M
Financials (TTM)
Gross Profit
$95.60M
Operating Income
-$640.25M
EBITDA
-$734.67M
Operating Cash Flow
-$523.85M
Capital Expenditure
-$25.07M
Free Cash Flow
-$548.92M
Cash & ST Invst.
$818.55M
Total Debt
$1.29B
Cytokinetics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$19.36M
+1125.8%
Gross Profit
$16.96M
+117.3%
Gross Margin
87.64%
N/A
Market Cap
$10.61B
N/A
Market Cap/Employee
$15.76M
N/A
Employees
673
N/A
Net Income
-$206.03M
-27.7%
EBITDA
-$169.32M
-24.4%
Quarterly Fundamentals
Total Cash
$818.55M
-12.8%
Total Debt
$1.29B
+62.9%
Accounts Receivable
$6.83M
+239.3%
Inventory
$154.00K
N/A
Long Term Debt
$1.22B
+61.2%
Short Term Debt
$65.77M
+102.2%
Return on Assets
-65.15%
N/A
Return on Invested Capital
-59.60%
N/A
Free Cash Flow
-$151.39M
-10.3%
Operating Cash Flow
-$145.46M
-10.5%